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In the absence of replication of wells, empirical criteria for enzyme-linked immunospot
(ELISpot) positivity use fixed differences or ratios between spot forming units (SFU) counts
between test and control. We propose an alternative approach which first identifies the
optimally variance-stabilizing transformation of the SFU counts, based on the Bland–Altman
plot of the test and control wells. The second step is to derive a positivity threshold from the
difference in between-plate distribution functions of the transformed test and control SFU
counts. This method is illustrated using 1309 assay results from a cohort study of influenza in
Vietnam in which some, but not all, of the peptide pools have clear tendencies for SFU countsAccepted 27 February 2013
Available online 7 March 2013
Keywords:
ELISpot
Cut-off to be higher in test than control wells.
Standardized© 2013 Elsevier B.V. Open access under CC BY license.1. Introduction
Since it was first described in 1983, the enzyme-linked
immunospot (ELISpot) assay has become awidely usedmethod
for the detection of antigen-specific cytokine-secreting T cells
(Czerkinsky et al., 1983; Versteegen et al., 1988), and is now a
standard assay for measuring the cell-mediated immune
response to vaccines in clinical trials. The requirement for
immunological assays used in vaccine trials to be rigorously
validated has resulted inmuchwork tomaximize the sensitivity





 BY license.minimize inter-laboratory and inter-operator variability and
to automate and standardize the counting of the spot forming
units (SFU) (Vaquerano et al., 1998; Schmittel et al., 2000;
Mwau et al., 2002; Janetzki et al., 2004, 2005, 2008; Cox et al.,
2005; Lehmann, 2005; Samri et al., 2006;Maecker et al., 2008).
However, criteria for defining a positive response have been
subject to considerable debate and controversy (Mwau et al.,
2002; Hudgens et al., 2004; Jamieson et al., 2006; Jeffries et al.,
2006; Moodie et al., 2010; Slota et al., 2011).
Since the spot counts in the negative control wells,
which contain no stimulating analyte, are predictive of the
background count in the wells that contain peptide (the
experimental wells) it makes sense to use comparisons between
the negative control and the experimental wells to define
responsiveness (Hudgens et al., 2004). This approach is further
supported by the variability in background spot counts between
and within laboratories and individuals, and even within
samples depending on their handling,whichmean that universal
cut-offs are generally not credible (Hudgens et al., 2004; Cox et
al., 2005). One commonly used technique to define a positive or
negative response is to consider a well positive if it contains a
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control well, with values of 10–50 SFU/106 PBMC often being
used (Schölvinck et al., 2004). This method has the
disadvantage of a higher false positive probability in plates
with high background, since a chance variation of, for
example, 10 spots is more likely with high counts than
low counts. A common alternative is to consider a well
positive if its number of SFU is above a pre-defined multiple
of the control, i.e. a criterion based on a ratio rather than a
difference. This has the opposite disadvantage: higher false
positive probability in plates with low background counts.
For example, if the criterion is a four-fold ratio, and the
negative control has two spots, an experimental well will be
considered positive if it has ≥eight spots, and this is much
more likely to occur by chance than a value of 800 spots
where the control well has 200. These considerations have
led many groups to apply a combination of absolute and fold
difference (Larsson et al., 1999; Russell et al., 2003; Jeffries et
al., 2006). For example, the T-SPOT manual recommends a
difference of at least 6 if the negative control has 5 or fewer
spots, and a ratio of at least 2 when it has 6 or more (Oxford
Immunotec, 2006). Additionally, a threshold value (e.g. at least
11 SFU/106 PBMC in the experimental well) is also sometimes
applied to provide a threshold of responsiveness that is
considered to have biological significance. Similarly, an
upper limit on the number of spots in the negative control
well may be imposed, e.g. 10 in the case of T-SPOT and IAVI
(International AIDS Vaccine Initiative)(Gill et al., 2010).
These cut-offs and thresholds are often definedwith reference to
ELISpot responses in a known negative population and are
therefore often referred to as empirical methods (Moodie et al.,
2006). By contrast, statistical methods have been developed
which use the variation between replicate controlwells to define
positivity thresholds (Hudgens et al., 2004; Moodie et al., 2006).
However, when a wide range of peptides is being examined it
may be impractical to include replication of the peptide and
negative control wells. In the current paper we develop a
positivity criterion for such plate layouts, in the context of a
study of cell mediated immunological response to influenza.2. Methods and results
We present a method which uses within-plate differences
between test and control wells, and a positivity threshold
based on their statistical distribution over plates. The method
relies on the principle that pools can only be reliably declared
positive when the test counts tend to be larger than the
negative control ones. The method is illustrated using data
from a cohort study in Vietnam (Horby et al., 2012).2.1. Study population
The cohort study included 932 individuals aged between
5 and 90 years. PBMC samples were taken to measure the
prevalence of T-cell responsiveness to seasonal and avian
influenza peptides in order to determine the protective effect
of pre-existing T-cell responses. Institutional review boards
in the United Kingdom and Vietnam approved the study and
all subjects provided written informed consent.2.2. ELISpot assay
2.2.1. Antigens
The complete proteome of H3N2 (A/NewYork/388/2005),
the haemagglutinin and neuraminidase of H1N1 (A/Hong Kong/
1134/98 andA/NewYork/228/2003) and the haemagglutinin of
H5N1 (A/Vietnam/CL26/2004) were represented as 14–20
amino acid peptides overlapping by 10 amino acids. Peptides
representing each protein were tested as either 1 or 2 pools
containing between 24 and 52 peptides, giving a total of 20
pools. The final culture concentration of individual peptideswas
2–3 μg/ml. Phytohemagglutinin (Sigma-Aldrich) was used at
10 μg/ml.
2.2.2. PBMC preparation and IFN-γ ELISpot
Heparinized venous bloodwas receivedwithin eight hours of
collection and immediately overlayed onto Lymphoprep then
centrifuged to isolate PBMCs. PBMCs were either tested in
ELISpot immediately or cryopreserved in fetal calf serum
containing 10% DMSO. ELISpot was performed according to
published protocols (Lalvani et al., 1997). In brief, 250,000
PBMC per well were incubated with peptide pools, PHA or
media-only (negative control) overnight. ELISpot plates
were scanned using a Cellular Technology Ltd. Series 3A
Analyzer. Spots were then counted using ImmunoSpot 3.1
software. Spot definition settings were as follows: sensitivity
170; minimum spot size 0.0142 mm2; maximum spot size
0.4399 mm2; oversized spots estimated; spot separation
1.00; diffuse spot process on; diffuseness 20; gradient off;
overdeveloped area handling active; background balance
on; background balance 30; fill holes off. Audit spots was
set ‘on’ such that automated counting was subject to manual
review whereby areas selected automatically could be de-
selected if they appeared to be something other than a spot
from IFN-γ release. PHA wells were counted using more
sensitive settings. Spot forming unit (SFU) counts were
automatically transferred from an automated ELISpot coun-
ter (Cellular Technology Limited) to a Microsoft Access
database, resulting in 1309 records. Of these, 758 were
tested immediately and 551 cryopreserved. We present
analysis of all samples irrespective of this status, although
supplementary figures show that test SFU counts exceeded
those of control more strongly in those samples processed
immediately.
2.3. Statistical methods
The approach is to first identify a suitable data transfor-
mation and then, where feasible, choose a threshold value to
define positive wells. This will be illustrated by two of the
H1N1 pools from the above study.
As mentioned above, thresholds based on differences
between spot counts tend to result in false positive at high
values, but those based on ratios — or, equivalently, differences
on the log scale— result in the opposite problem. This is because
the variance of the untransformed counts increases with the
mean value, and this trend is reversed by the logarithmic
transformation. The property of the variance changing with the
mean — whether increasing or decreasing — is known as
heteroscedasticity. Since the logarithmic transformation
can be seen as the limit of a series of power transformations
Fig. 1. Bland–Altman plots for the power-transformed counts for
haemagglutinin (upper panel) and neuraminidase (lower panel). Each
vertical axis is the difference between the transformed test and control
values. Each horizontal axis is the average of the transformed values, on a
log scale. In the main part of each plot, to the left, the points are arranged
in curved lines because of the original data are integers (whole numbers). In
particular, the curved line closest to the top left corner of each plot contains
samples with a zero control result (but varying test counts), and the line closest
to the bottom left corner contains those with a zero test result (but varying
control counts). The solid points are those which would be positive on the
T-SPOT criteria, either for test minus control, or ‘pseudo-positives’ in which
control minus test wouldmeet those same criteria. The power whichminimizes
the relation between the variance and mean of the differences in transformed
counts is 0.26 for haemagglutinin and 0.27 for neuraminidase. Towards the right
of each plot there is a histogram of the differences between the transformed
values of test and control, using the same vertical axis. For haemagglutinin, but
not for neuraminidase, there is a visible pattern of positives predominating over
pseudo-positives.
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the power which minimizes heteroscedasticity. More specifi-
cally, for each power we plot the difference of the transformed
values against their average— a Bland & Altman plot (Bland and
Altman, 1986)— andminimize the chi-squared statistic of a test
for heteroscedasticity in the corresponding regression (Breusch
and Pagan, 1979). We also used the studentized version of the
test, which is more robust to non-Gaussian variation (Koenker,
1981), and the results remained identical to at least twodecimal
places. Once the power transformation has been selected, the
regression is not used further.
For the 20 pools, the selected powers ranged from 0.23 to
0.31, mean 0.27. In other words, the optimal transformations
were close to fourth root (power = 1/4). Fig. 1 shows the Bland
and Altman plots for the first haemagglutinin pool, and the
second neuraminidase pool. These plots also show i) the test
wells positive on the T-SPOT criteria (see Introduction), and ii)
the control wells which would have been positive on the same
criteria, had the test and control status been reversed, here-
after referred to as pseudo-positive. For haemagglutinin, the
T-SPOT-positive test wells greatly outnumber the pseudo-
positive control wells (247:46), but this is not the case for
neuraminidase (58:59). By quartile on the horizontal axis, the
proportions positive on the T-SPOT criteria are: 0, 23, 26 and
32% for haemagglutinin and 0, 0, 6 and 16% for neuraminidase.
To select a threshold value for defining positive wells,
we use the principle that test minus control values should,
on average, be larger than control minus test. Otherwise,
there is no evidence of a ‘signal’ over the ‘noise’ of control
variation, and any positivity threshold is dubious. To select
the threshold we compare the empirical cumulative distri-
bution functions (ECDFs) of i) test–control for those plates
with test > control and ii) control–test for those with
control > test. The ECDF of a sample is simply the proportion
of the data points which lie at or below a given value. The
difference between ECDFs can be used to discriminate between
a mixture of two distributions. In particular, the value which
maximizes the difference in ECDFs also maximizes the proba-
bility of correct classification (Stoller, 1954). Hence, for the
current purpose, we choose the threshold to be the value
which maximizes the difference between the above two
ECDFs. Pools whose difference over control exceeds this
value are declared positive. In principle it is possible for this
maximum difference in ECDFs to occur at more than one value
on the horizontal axis. Hence we define the threshold, more
precisely, to be the lowest such value on the horizontal axis.
This is shown in Fig. 2 for the two selected pools. Greater
data values shift the ECDF to the right, making it lower at
any given point on the horizontal axis. For haemagglutinin,
the ECDFs of test-minus-control and control-minus-test are
much more widely separated than for neuraminidase. For
haemagglutinin, the maximum difference in ECDFs is 0.22
and occurs at a transformed test-minus-control value of 1
(i.e. a value greater than 1 is considered positive). For
neuraminidase the maximum difference in ECDFs is 0.11
and occurs at a test-minus-control value of 0.64. Applying
these threshold values to Fig. 1 gives 291 positive test wells
and 63 pseudo-positive control wells for haemagglutinin.
The corresponding numbers for neuraminidase are much
closer — 222 and 204 — suggesting that reliable discrim-
ination is not possible for neuraminidase. By quartile of thetransformedmean, the proportions positive for haemagglutinin
are: 0, 68, 13 and 15%, and for neuraminidase are 22, 50, 12 and
11%.
The maximum difference between the two ECDFs is also
used by the Kolmogorov–Smirnov test for differences between
distributions. A large p value from this test would again suggest
Fig. 2. Empirical cumulative distribution functions (ECDF, vertical axis) for
the power-transformed positive differences (horizontal axis) of i) test over
control (solid line) and ii) control over test (dashed line). The upper panel
shows haemagglutinin and the lower one neuraminidase. Each ECDF is the
proportion of data points below the corresponding value on the horizontal
axis. Each vertical line indicates the greatest separation of the two ECDFs. For
haemagglutinin, the ECDFs are further apart than for neuraminidase,
indicating a greater tendency for the haemagglutinin test wells to have
more SFU than the negative control.
Fig. 3. For each panel (upper haemagglutinin, lower neuraminidase), the
horizontal axis is the difference between the power-transformed test
and control count values. For each such value, the vertical axis shows the
corresponding tail probability, i.e. the proportion of the upper and lower
tails which is found in the upper tail. For example a proportion of 75%
means that the upper tail (test exceeding control by a given amount) has
three times as many data points as the lower tail (control exceeding test
by that amount). Values near to 50% indicate control SFU counts being, on
average, about as high as test. The solid vertical lines are the 95% exact
binomial confidence interval for each proportion. These become wide at
high values because they are based on few data points. The dashed
vertical line on each figure are at the same values as the corresponding
panel of Fig. 2. Haemagglutinin, but not neuraminidase, shows a clear
‘signal’ of test over control.
60 N. Alexander et al. / Journal of Immunological Methods 392 (2013) 57–62that reliable identification of positive samples is not possible,
although the converse is not necessarily true. In other words,
the p value being less than 5%, for example, does not imply that
reliable identification will be possible. Rather, the hypothesis
test screens out examples for which no reliable identification
can be expected (Armitage et al., 2001, page 472). Over all 20
pools, the p values ranged from 2 × 10−16 to 0.67, those for
haemagglutinin and neuraminidase being 2 × 10−9 and 0.02
respectively. Hence for some pools there is no tendency for test
to exceed control, as opposed to the other way round, and in
such cases trying to assign a threshold would be futile.This analysis can be expressed in terms of the probability
of correctly identifying which pool is test and which is
control, when this status is unknown. Suppose we have i) one
person's test and control results x and y (possibly on a
transformed scale), x being the larger, but without knowing
whether x or y is test, and ii) the distribution of previous
test-minus-control values (with the experimental conditions
61N. Alexander et al. / Journal of Immunological Methods 392 (2013) 57–62known). We expect larger values to result from the test
condition, so suppose our rule is to conclude that x is from the
test condition if it exceeds the smaller one by more than a value
k. The conditional probability that x is the test sample, given that
x − y > k, is
Probðx is test x−y > kj Þ ¼ Prob x is test & x−y > kð Þ
Prob x−y > kð Þ
¼ Prob x is test & x−y > kð Þ
Prob x is test & x−y > kð Þ þ Prob x is control& x−y > kð Þ
This last expression is the area of the upper tail of the
distribution (above a test-minus-control value of k) divided by
the sum of the upper and lower tails (above k or below−k). If
the control value rarely exceeds the test by k, then this
probability will be high. This argument is applied to the cohort
data in Fig. 3. For haemagglutinin, the test value is likely
to exceed control, for a wide range of threshold values. For
neuraminidase, however, the control value is about as likely
to exceed test as the other way round.
Results from simulated data confirm that the proportion of
samples identified as positive increases with the excedent test
mean over the control mean (see Supplementary Material).
These results also suggest that the current approach may be
conservative in identifying positives. There is also a high degree
of variation in the estimated proportion positive, which to some
extent results from the high variation in the input data. All
analysis uses R version 2.11, and the custom-written functions
are also included as supplementary material.
3. Discussion
Replication of ELISpot test and control wells has been
recommended (Moodie et al., 2010) although it reduces
the number of proteins that can be tested for given resources.
Existing statistical methods utilize this replication to define
positivity criteria objectively based on within-plate, between-
replicate, variation (Moodie et al., 2012). In the absence of
replication, the current approach relies on between-plate
variation in a sizable dataset from a given population. The
principle is that positivity should tend to give test wells
larger counts than control wells.
One problem with existing empirical cut-offs is that large
absolute differences are likely to happen by chance when spot
counts are high. Log transformation reverses the problem
because large fold changes from control can occur by chance at
low spot counts. In statistical terms, the original and transformed
datasets both have heteroscedasticity, i.e. variance associated
with the mean. One solution is to use a transformation which is
less strong than the logarithm. The square root transformation
may suffice, for example, when the same parasite slide is read
twice. This corresponds to the theoretical minimum variation,
described by the Poisson distribution of homogeneous counts
(Alexander et al., 2007). The current approach selects the power
transformation which minimizes heteroscedasticity in the Bland
&Altmanplot. All of the pools in the example datasetwere found
to have optimal powers close to ¼, i.e. fourth root transforma-
tion,which is between the square root and logarithm in strength.
It was notable that some protein test pools had little or no
tendency to exceed the negative (medium) control in terms
of spot count. Seeking positive samples is quixotic in thesecircumstances. In particular, applying existing empirical
criteria to such pools, the number of test wells declared positive
barely exceeds the number of control wells which would have
beendeclared positive, had the test/control status been reversed
in the analysis. When there is a tendency for the differences of
test over control to exceed those of control over test, a positivity
cutoff can be chosen by comparing their empirical distribution
functions (ECDFs), by analogy with non-parametric discrimina-
tion (Stoller, 1954). The value corresponding to the maximum
difference between the ECDFs gives the greatest probability of
successful classification. In practice, however, false negative and
false positive errors may not have equal importance, which
would suggest increasing or decreasing the cut-off. This kind of
calibration, e.g. by receiver operating characteristic (ROC) curve,
would require independent identification of true positive and
negative individuals. For influenza it is difficult to identify
unexposed people from whom to prepare negative sera for this
purpose. Such an approach should be more feasible for other
infections such as HIV and tuberculosis.
4. Conclusions
For situations in which replication of wells is infeasible,
we highlight problems with positivity criteria based on fixed
differences or ratios between test and control wells, which
are known as empirical methods. In our example dataset
from a large cohort study, we show that some peptide pools
can often be positive on such empirical criteria, while having
little or no elevation in SFU over the negative control. We
propose an alternative approach which uses within-plate
differences between test and control wells, and a positivity
threshold based on their statistical distribution over plates.
Supplementary data to this article can be found online at
http://dx.doi.org/10.1016/j.jim.2013.02.014.
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